Get the Stockscreener App
38.15
0.56%
0.34
Apogee Therapeutics Inc stock is traded at $38.15, with a volume of 64,952.
It is up +0.56% in the last 24 hours and up +19.56% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$37.81
Open:
$38.14
24h Volume:
64,952
Relative Volume:
0.10
Market Cap:
$2.29B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-13.85
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
-5.23%
1M Performance:
+19.56%
6M Performance:
-37.79%
1Y Performance:
-28.16%
1-Day Range:
$37.93
$39.45
1-Week Range:
$34.38
$40.15
52-Week Range:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
38.10 | 2.29B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.95 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.84 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
563.65 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.15 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
234.20 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
APGE August 15th Options Begin Trading - Nasdaq
Stifel maintains $95 target on Apogee Therapeutics stock By Investing.com - Investing.com Nigeria
(APGE) On The My Stocks Page - news.stocktradersdaily.com
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade - Yahoo Finance
Apogee Therapeutics, Inc. (NASDAQ:APGE) Holdings Lowered by Invesco Ltd. - Defense World
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - The Manila Times
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference - GlobeNewswire Inc.
Wells Fargo & Company MN Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
JPMorgan Chase & Co. Has $1.69 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
It would be worthwhile to take a closer look at Apogee Therapeutics Inc (APGE) - uspostnews.com
Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth - Yahoo Finance
First Week of APGE June 20th Options Trading - Nasdaq
When (APGE) Moves Investors should Listen - news.stocktradersdaily.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Geode Capital Management LLC Has $36.98 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics: Engineering Biologic Dominance (NASDAQ:APGE) - Seeking Alpha
Vanguard Group Inc. Sells 29,445 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Commonwealth Equity Services LLC Buys Shares of 4,906 Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
KLP Kapitalforvaltning AS Acquires New Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Insider Purchases Worth US$990.8k See Losses As Apogee Therapeutics Market Value Drops To US$1.9b - simplywall.st
Corebridge Financial Inc. Cuts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics’ chief medical officer sells $139,801 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics’ chief medical officer sells $139,801 in stock - Investing.com Australia
Teacher Retirement System of Texas Purchases 1,848 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17 - The AM Reporter
Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
(APGE) Trading Advice - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
12 Best IPO Stocks to Buy in 2025 - Insider Monkey
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World
Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading Up 4.5%What's Next? - MarketBeat
Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com
Apogee Therapeutics initiated with a Buy at Citi - TipRanks
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):